PMID- 16137436
OWN - NLM
STAT- MEDLINE
DCOM- 20051207
LR  - 20151119
IS  - 1526-8209 (Print)
IS  - 1526-8209 (Linking)
VI  - 6
IP  - 3
DP  - 2005 Aug
TI  - Hormone receptor status does not affect the clinical benefit of trastuzumab 
      therapy for patients with metastatic breast cancer.
PG  - 247-52
AB  - BACKGROUND: Hormone receptor (HR) and HER2 signaling pathways are involved in the 
      regulation of breast cancer proliferation. The impact of HR status on the 
      clinical outcome of patients with HER2-overexpressing disease treated with the 
      monoclonal antibody trastuzumab is unknown. PATIENTS AND METHODS: To evaluate 
      this, we conducted a retrospective analysis of 805 patients with metastatic 
      breast cancer enrolled in 3 clinical trials comparing trastuzumab in combination 
      with chemotherapy versus chemotherapy alone or trastuzumab monotherapy as first-, 
      second-, or third-line treatment. Patients whose tumor samples overexpressed HER2 
      by fluorescence in situ hybridization (FISH) were stratified based on HR status, 
      and clinical outcomes were compared. RESULTS: Tumor samples from 596 of 805 
      patients were HER2overexpressing by FISH; 45% of these were HR-positive and 43% 
      were HR-negative (HR status was unknown in 12%). Overall response rate (ORR) and 
      time to progression (TTP) were significantly higher in patients treated with 
      chemotherapy plus trastuzumab than in those treated with chemotherapy alone, 
      irrespective of HR status. Median survival was longer for patients with 
      HR-positive tumors receiving combination therapy compared with those with 
      HR-negative tumors. In the trastuzumab monotherapy trials, ORR and TTP were 
      similar for patients with HR-positive and HR-negative tumors. Median survival was 
      longer for patients with HR-positive tumors compared with those with HR-negative 
      tumors. CONCLUSION: Hormone receptor status did not affect the clinical benefit 
      of trastuzumab given as a single agent or combined with chemotherapy. The 
      addition of trastuzumab to chemotherapy provides an improved clinical benefit 
      compared with chemotherapy alone, regardless of HR status.
FAU - Brufsky, Adam
AU  - Brufsky A
AD  - Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
FAU - Lembersky, Barry
AU  - Lembersky B
FAU - Schiffman, Kathy
AU  - Schiffman K
FAU - Lieberman, Grazyna
AU  - Lieberman G
FAU - Paton, Virginia E
AU  - Paton VE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Steroid)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/genetics/*metabolism/pathology
MH  - Clinical Trials as Topic
MH  - Female
MH  - Genes, erbB-2/physiology
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Receptors, Steroid/*biosynthesis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Trastuzumab
MH  - Treatment Outcome
EDAT- 2005/09/03 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/03 09:00
PHST- 2005/09/03 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/03 09:00 [entrez]
AID - S1526-8209(11)70727-3 [pii]
AID - 10.3816/CBC.2005.n.027 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2005 Aug;6(3):247-52. doi: 10.3816/CBC.2005.n.027.